et-400 — NDA/BLA filed

“On April 30, 2024, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ET-400, the Company's proprietary patented formulation of hydrocortisone oral solution.”